Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debanjali Mitra

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Future Oncology (London, England)|September 13, 2018
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancerChristina Darden, Debanjali Mitra, David McSorley, et al.
Applied Health Economics and Health Policy|June 30, 2009
Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked databaseKeith L Davis, Debanjali Mitra, Srividya Kotapati, et al.
Journal of Managed Care & Specialty Pharmacy|May 27, 2015
Health care resource utilization and costs associated with nonfatal major adverse cardiovascular eventsJennifer S Korsnes, Keith L Davis, Rinat Ariely, et al.
International Journal of Hematology|March 31, 2012
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review studyPeter C Trask, Debanjali Mitra, Shrividya Iyer, et al.
Breast (Edinburgh, Scotland)|November 5, 2018
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS studyGavin Taylor-Stokes, Debanjali Mitra, John Waller, et al.
International Journal of Hematology|February 22, 2012
Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review studyDebanjali Mitra, Peter C Trask, Shrividya Iyer, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|February 21, 2007
Localization and thyroid hormone influenced expression of collagen II in ovarian tissueSamir Saha, Pamela Ghosh, Debanjali Mitra, et al.
Journal of Studies on Alcohol. Supplement|October 15, 2005
Cost methodology of COMBINEGary A Zarkin, Jeremy W Bray, Debanjali Mitra, et al.
Cancer Treatment and Research Communications|May 14, 2022
Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS studyKatie Mycock, Lin Zhan, Kieran Hart, et al.
American Journal of Clinical Dermatology|October 23, 2024
Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical TrialRodney Sinclair, Natasha Mesinkovska, Debanjali Mitra, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Future Oncology (London, England)|September 13, 2018
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancerChristina Darden, Debanjali Mitra, David McSorley, et al.
Applied Health Economics and Health Policy|June 30, 2009
Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked databaseKeith L Davis, Debanjali Mitra, Srividya Kotapati, et al.
Journal of Managed Care & Specialty Pharmacy|May 27, 2015
Health care resource utilization and costs associated with nonfatal major adverse cardiovascular eventsJennifer S Korsnes, Keith L Davis, Rinat Ariely, et al.
International Journal of Hematology|March 31, 2012
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review studyPeter C Trask, Debanjali Mitra, Shrividya Iyer, et al.
Breast (Edinburgh, Scotland)|November 5, 2018
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS studyGavin Taylor-Stokes, Debanjali Mitra, John Waller, et al.
International Journal of Hematology|February 22, 2012
Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review studyDebanjali Mitra, Peter C Trask, Shrividya Iyer, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|February 21, 2007
Localization and thyroid hormone influenced expression of collagen II in ovarian tissueSamir Saha, Pamela Ghosh, Debanjali Mitra, et al.
Journal of Studies on Alcohol. Supplement|October 15, 2005
Cost methodology of COMBINEGary A Zarkin, Jeremy W Bray, Debanjali Mitra, et al.
Cancer Treatment and Research Communications|May 14, 2022
Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS studyKatie Mycock, Lin Zhan, Kieran Hart, et al.
American Journal of Clinical Dermatology|October 23, 2024
Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical TrialRodney Sinclair, Natasha Mesinkovska, Debanjali Mitra, et al.
Pageof 5